BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of “Moderate Buy” by Brokerages

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $365.7857.

Several research firms recently commented on ONC. Barclays began coverage on BeOne Medicines in a research note on Thursday, September 18th. They set an “overweight” rating and a $385.00 target price for the company. Citigroup boosted their price objective on BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Truist Financial set a $400.00 target price on shares of BeOne Medicines in a report on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday, December 17th.

BeOne Medicines Stock Down 0.7%

BeOne Medicines stock opened at $310.30 on Tuesday. The firm has a market capitalization of $36.78 billion, a P/E ratio of 608.43 and a beta of 0.45. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. BeOne Medicines has a twelve month low of $172.67 and a twelve month high of $385.22. The stock’s fifty day simple moving average is $327.16 and its 200-day simple moving average is $310.20.

Insiders Place Their Bets

In other news, COO Xiaobin Wu sold 10,000 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $356.02, for a total value of $3,560,200.00. Following the transaction, the chief operating officer owned 6,009 shares in the company, valued at approximately $2,139,324.18. This represents a 62.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,627 shares of the firm’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $340.90, for a total value of $895,544.30. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 138,617 shares of company stock worth $44,632,898. 6.62% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds have recently added to or reduced their stakes in the stock. Anchor Investment Management LLC purchased a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of BeOne Medicines in the 2nd quarter valued at $28,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines during the 2nd quarter worth $35,000. Farther Finance Advisors LLC purchased a new stake in BeOne Medicines in the second quarter valued at $39,000. Finally, Signaturefd LLC purchased a new stake in BeOne Medicines in the second quarter valued at $49,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.